SLU-PP-332

SLU-PP-332 (referred to as 'Slooh') has essentially no meaningful oral bioavailability because the compound does not dissolve in water. The researchers who studied it acknowledged this as the primary limitation of the drug. Without water solubility, the molecule cannot adequately pass through the gut lining to be absorbed into systemic circulation.

The speaker explicitly warns that none of the proposed stacking combinations (GLP-1 with AOD, SLUPP332, MOTS-c, or 0304) have been tested together in human trials. Therefore, determining which layers belong in a plan and their order is a clinical decision requiring medical supervision rather than following generic 'stack lists.'

SLUPP332 is described as a 'cellular enhancement' compound that increases energy expenditure in metabolically active tissue, particularly skeletal muscle. It is referred to as an 'exercise in a bottle' because it enhances fat oxidation during activity. It does not address hunger and serves as a layer for energy complaints rather than appetite suppression.

Given the near-zero oral bioavailability of SLU-PP-332, consumers purchasing oral formulations of this compound should be aware they are unlikely to receive any meaningful systemic exposure. The compound's inability to dissolve in water means that standard oral capsule or tablet formulations are fundamentally flawed delivery vehicles. This represents an implicit safety and efficacy warning for anyone considering oral SLU-PP-332 supplementation.

The only scenario in which SLU-PP-332 might achieve any meaningful oral absorption is when consumed alongside a high-fat meal, likely due to fat-mediated solubilization in the gut. However, even under this condition, absorption is described as a coin flip — the compound may still be digested or degraded before it can reach the gut lining. This makes oral dosing of SLU-PP-332 highly unpredictable and unreliable.

For any orally consumed compound to be absorbed, it must be able to dissolve in water so it can interact with and pass through the gut lining. Compounds that lack water solubility face a fundamental barrier to oral bioavailability regardless of their intrinsic biological activity. This is presented as a general mechanistic principle applicable beyond just SLU-PP-332.

The bioavailability problems identified with SLU-PP-332 directly motivated researchers to develop SLU-PP-915 as a successor compound. The explicit goal of SLU-PP-915 was to address the oral bioavailability deficiencies of SLU-PP-332. This suggests SLU-PP-915 may have improved water solubility or formulation characteristics.

The speaker articulates a general pharmacokinetic principle: for any orally consumed molecule to be absorbed through the gut lining into the body, it must be water-soluble. Compounds that lack water solubility face a fundamental barrier to oral bioavailability regardless of dose. This is presented as a broadly applicable warning for anyone considering oral administration of poorly soluble research compounds.

The poor oral bioavailability of SLU-PP-332 directly motivated the development of a successor compound, SLU-PP-915. The implication is that SLU-PP-915 was engineered with improved solubility or absorption characteristics to overcome the limitations identified with SLU-PP-332. No dosage or clinical outcome data for SLU-PP-915 is provided in this excerpt.

A key mechanistic warning is raised: compounds that do not dissolve in water are at high risk of being digested or chemically destroyed in the gastrointestinal tract before they can reach the gut lining for absorption. This is presented as a general principle applicable to any orally consumed molecule with poor water solubility. For SLU-PP-332 specifically, this means oral formulations are likely ineffective and potentially wasteful or misleading for consumers.

The only scenario in which SLU-PP-332 might achieve any meaningful oral absorption is when consumed alongside a high-fat meal, which could aid in dissolving the lipophilic compound. Even under this condition, absorption is described as essentially a coin flip, as the compound may still be digested or degraded before reaching the gut lining. This makes oral dosing of SLU-PP-332 highly unpredictable and unreliable.

The bioavailability problems identified with SLU-PP-332 directly motivated researchers to develop SLU-PP-915 as an improved analog. SLU-PP-915 was specifically designed to address the oral bioavailability deficiencies of its predecessor. This suggests an active research effort to create a more clinically viable version of the compound.

The speaker explains that SLUPP-332 works through mitochondrial uncoupling, a process whereby cells dissipate energy as heat rather than storing it as ATP, resulting in increased fuel combustion. This mechanism is presented as the biological basis for its metabolic and exercise-mimicking effects. No supporting study citations are provided.

SLUPP-332 is presented as a potential tool for individuals who cannot exercise due to chronic fatigue or physical injury, effectively filling the physiological gap left by the absence of physical activity. The speaker frames it as a clinical tool for specific patient populations. No dosage or protocol details are provided.

The speaker claims SLUPP-332 can reset cellular metabolic machinery in individuals whose metabolism has been suppressed or 'crashed' due to chronic dieting. The mechanism proposed is mitochondrial-level restoration of normal energy production. No dosage or protocol details are provided.

SLUPP-332 is described as an exercise mimetic that tricks mitochondria into behaving as though the body has performed significant aerobic exercise (equivalent to running 5 miles). The speaker claims it increases oxidation, boosts energy production, and elevates metabolic rate. No dosage, frequency, or administration route is mentioned in the transcript.

The speaker says 'loop 332', the caption rendering of SLU-PP-332, upregulates mitochondria, increasing resting energy expenditure. SLU-PP-332 is a synthetic estrogen-related receptor agonist studied as an exercise mimetic in animals; it is not a peptide. [Audit 2026-10-04: identified 'loop 332' as SLU-PP-332]